+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Evaluation of radioactivity in the bodies of mice induced by neutron exposure from an epi-thermal neutron source of an accelerator-based boron neutron capture therapy system


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          This study aimed to evaluate the residual radioactivity in mice induced by neutron irradiation with an accelerator-based boron neutron capture therapy (BNCT) system using a solid Li target. The radionuclides and their activities were evaluated using a high-purity germanium (HP-Ge) detector. The saturated radioactivity of the irradiated mouse was estimated to assess the radiation protection needs for using the accelerator-based BNCT system. 24Na, 38Cl, 80mBr, 82Br, 56Mn, and 42K were identified, and their saturated radioactivities were (1.4 ± 0.1) × 10 2, (2.2 ± 0.1) × 10 1, (3.4 ± 0.4) × 10 2, 2.8 ± 0.1, 8.0 ± 0.1, and (3.8 ± 0.1) × 10 1 Bq/g/mA, respectively. The 24Na activation rate at a given neutron fluence was found to be consistent with the value reported from nuclear-reactor-based BNCT experiments. The induced activity of each nuclide can be estimated by entering the saturated activity of each nuclide, sample mass, irradiation time, and proton current into the derived activation equation in our accelerator-based BNCT system.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Effectiveness of BNCT for recurrent head and neck malignancies.

          Recurrent head and neck malignancies (HNM) are often radio-/chemo-resistant and show extensive growth, necessitating a wide resection including surrounding tissues. To avoid severe impairment of oro-facial structures and functions, it is necessary to explore new treatments for HNM. Boron neutron capture therapy (BNCT) is tumor-cell targeted radiotherapy that has significant superiority over conventional radiotherapies in principle. We report here, first in the world, six patients with a recurrent HNM who have been treated with BNCT. The BNCT in combination with boronophenylalanine (BPA) and borocaptate sodium (BSH) was performed using the epithermal neutrons with Kyoto University Research Reactor (KUR). The results of BNCT were as follows: (1) (10)B concentration of tumor/normal tissue ratios (T/N ratio) of PET studies were SCC:1.8-4.4, sarcoma:3.1-4.0, parotid tumor:3.5. (2) Relative volume (%) of each tumor to the prior were 6-46%. (3) Remarkable reduction (46-100%) of huge tumor such as 40-675 cm(3) (average: 315 cm(3)), improvement of QOL and very mild side effects were recognized in all cases. These results indicate that BNCT represents a new and promising treatment approach even for a huge or far advanced HNM.
            • Record: found
            • Abstract: found
            • Article: not found

            Fractionated Boron Neutron Capture Therapy in Locally Recurrent Head and Neck Cancer: A Prospective Phase I/II Trial.

            To investigate the efficacy and safety of fractionated boron neutron capture therapy (BNCT) for recurrent head and neck (H&N) cancer after photon radiation therapy.
              • Record: found
              • Abstract: not found
              • Article: not found

              Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound.


                Author and article information

                Proc Jpn Acad Ser B Phys Biol Sci
                Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci
                Proceedings of the Japan Academy. Series B, Physical and Biological Sciences
                The Japan Academy (Tokyo, Japan )
                11 December 2017
                : 93
                : 10
                : 821-831
                [*1 ]Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
                [*2 ]Department of Physics, Rikkyo University, Tokyo, Japan.
                [*3 ]Division of Research and Development for boron neutron capture therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan.
                [*4 ]Division of Genetics, National Cancer Center Research Institute, Tokyo, Japan.
                [*5 ]High Energy Accelerator Research Organization (KEK), Ibaraki, Japan.
                [*6 ]Department of Radiological Technology, National Cancer Center Hospital, Tokyo, Japan.
                [*7 ]Department of Medical Physics, Graduate School of Medicine, Tokyo Women’s University, Tokyo, Japan.
                [*8 ]Department of Frontier Life Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
                Author notes
                []Correspondence should be addressed: S. Nakamura, Department of Radiation Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan (e-mail: satonaka@ 123456ncc.go.jp ).

                (Communicated by Takashi SUGIMURA, M.J.A.)

                © 2017 The Japan Academy

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                : 26 May 2017
                : 8 September 2017
                Original Article

                Life sciences
                boron neutron capture therapy (bnct),accelerator-based bnct,induced radioactivity,radioactivation


                Comment on this article